155 related articles for article (PubMed ID: 29851465)
1. Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Roy J; Kaake M; Srinivasarao M; Low PS
Bioconjug Chem; 2018 Jul; 29(7):2208-2214. PubMed ID: 29851465
[TBL] [Abstract][Full Text] [Related]
2. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
3. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
5. Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers.
Roy J; Kaake M; Low PS
Oncotarget; 2019 Jan; 10(2):152-160. PubMed ID: 30719210
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
7. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
8. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
Li X; Shen B; Chen Q; Zhang X; Ye Y; Wang F; Zhang X
BMC Cancer; 2016 Mar; 16():251. PubMed ID: 27021903
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
11. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A
Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Leamon CP; Reddy JA; Bloomfield A; Dorton R; Nelson M; Vetzel M; Kleindl P; Hahn S; Wang K; Vlahov IR
Bioconjug Chem; 2019 Jun; 30(6):1805-1813. PubMed ID: 31075200
[TBL] [Abstract][Full Text] [Related]
14. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
[TBL] [Abstract][Full Text] [Related]
15. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
Emons G; Schally AV
Hum Reprod; 1994 Jul; 9(7):1364-79. PubMed ID: 7962452
[TBL] [Abstract][Full Text] [Related]
16. Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers.
Kanduluru AK; Low PS
Mol Pharm; 2017 Nov; 14(11):3859-3865. PubMed ID: 28969417
[TBL] [Abstract][Full Text] [Related]
17. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
[TBL] [Abstract][Full Text] [Related]
18. Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.
Engel JB; Tinneberg HR; Rick FG; Berkes E; Schally AV
Curr Drug Targets; 2016; 17(5):488-94. PubMed ID: 26951061
[TBL] [Abstract][Full Text] [Related]
19. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer.
Obayemi JD; Salifu AA; Eluu SC; Uzonwanne VO; Jusu SM; Nwazojie CC; Onyekanne CE; Ojelabi O; Payne L; Moore CM; King JA; Soboyejo WO
Sci Rep; 2020 May; 10(1):8212. PubMed ID: 32427904
[TBL] [Abstract][Full Text] [Related]
20. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
Schally AV; Nagy A
Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]